Please find enclosed Annual Report for the financial year 2024-2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Vivo Bio Tech has submitted its Annual Report for FY 2024-2025 along with the notice convening its 38th Annual General Meeting, scheduled for September 30, 2025 at 3:00 PM via Video Conferencing. The company is a pre-clinical Contract Research Organization (CRO) based in Hyderabad with a 53-acre GLP-compliant campus. For FY25, revenue stood at approximately ₹51.48 crore, EBITDA at ₹15.91 crore (adjusted ₹20.98 crore excluding one-time land sale profit of ₹4.62 crore), and net profit at ₹2.20 crore. The company highlighted a breakthrough ₹10.5 crore data generation contract with an agro-chemical company under Section 9.3, marking its first contract of this kind. Promoter holding stands at 40.85% with public shareholders at 59.15%, and the company employs 180 professionals out of a 260-strong workforce.
Routine regulatory filing — shareholders should review the annual report for detailed financials and watch for resolutions to be voted on at the September 30 AGM, including via e-voting. The ₹10.5 crore breakthrough contract and expansion into medical device testing, large animal studies, and potential NHP research could drive future revenue growth if successfully executed.